Drug intelligence / Profile preview

ABO-203

Development stage: Preclinical
Lead developer: Arbor Biotechnologies
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Programmable Nucleases → Gene Editing → Gene Therapies

Overview

ABO-203 is an AAV-based gene therapy developed by Arbor Biotechnologies. It utilizes nuclease excision technology for delivery and is designed to target specific regions of the brain to address the underlying genetic drivers of Amyotrophic Lateral Sclerosis (ALS). This approach aims to provide long-lasting therapeutic effects by modifying genetic material.

Beyond the preview

Go deeper on ABO-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABO-203.

Explore the full profile